Home / News / India News / Article /
DCGI gives nod to Bharat Biotech to conduct vaccine trials on humans
Updated On: 30 June, 2020 08:58 PM IST | New Delhi | ANI
Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19"
This picture has been used for representational purposes
New Delhi: The Drug Controller General of India (DCGI) has granted permission to Bharat Biotech International Limited (BBIL) to conduct Phase I and II Human clinical trials to develop an indigenous vaccine for COVID-19 -- in the name COVAXIN.
For this, Indian Council of Medical Research (ICMR) and BBIL had partnered to develop a fully indigenous vaccine for COVID-19 using the virus strain isolated at ICMR's National Institute of Virology (NIV), Pune.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT